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The human body is more than the sum of
its organs. Yet for hundredsof years,medi-
cine andmedical research have divvied up
the totality of the person into diseases that
are organ specific and characterized
largely by their phenotypic presentation.
These divisions are also reflected in
the organization of academic medical
centers and pharmaceutical research and
development and even permeate the fund-
ing of biomedical research, with disease-
centeredNIH institutesandprivate founda-
tions. This is understandable, and I am not
suggesting that it should be eliminated
because it is still a critical structure for
delivering patient care. But in research,
our understanding of the functioning of
the body and the causes of disease has
progressed beyond the phenotypic, and I
would argue that the present structure
has led to the curtaining off of one organ
or disease from its brethren. An individual
is the sum of their medical history, and
having one disease can greatly alter the
likelihood of having another. We know
now that chronic inflammation also
increasescancer risk (e.g., ulcerativecolitis
and colorectal cancer) and is also a risk
factor for obesity and neurodegeneration.
These comorbidities can be explained in
terms of common cellular and molecular
pathways. We need to think of new ways
to organize research into hubs informed
by common themes—for example, the
agingprocess or geneticmedicine—where
physician scientists and basic researchers
from different traditional disciplines can
come together. In this way, we can begin
to see behind the curtain that divides one
branch of knowledge from another.Progress through Partnership
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Despite remarkable achievements in basic
neuroscience, effective therapies are still
lacking for many neurological disorders,
such as stroke, Alzheimer’s disease, and
spinal cord injury. Strong curiosity-driven
basic research remains fundamental for
clinical advancements. However, for basic
research to have a greater impact on clin-
ical challenges, cliniciansmust be involved
from an earlier stage and not just immedi-
ately prior to application in patients.
Basic scientists should be educated in
the clinical features of neurological
disease and the problems related to diag-
nosis and therapy. Better animal models
that reflect the complex pathology and
pathogenesis of neurological disease
have to be developed in collaboration
with clinicians. Many current models use
otherwise healthy, young animals, which
is far from the clinical situation in which
patients are often older, with concurrent
diseases and chronic medication.
Basic scientists and clinicians together
have to develop functional and behavioral
tests in animals that assess deficits
resembling impairments in patients. The
new imaging techniques for monitoring
brain and spinal cord in vivo in animals
and humans create golden opportunities
for interaction between basic scientists
and clinicians.
The critical scientific steps from basic
research to patient application should be
defined in cooperation between basic
scientists and clinicians. This partnership
must function throughout all stages of clin-
ical translation if basic research findings
are to be efficiently converted to novel
treatments for neurological disorders.Cell 148Do Traits Influence Therapy?
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A rapidly growing number of genetic loci
have been linked to characteristic traits.
This often leaves clinicians wondering
the meaning for their individual patients.
This is especially true when the ability to
query a particular locus outpaces under-
standing of its clinical implications.
Transgenic methods of gene activation,
deletion, and substitution in cells and
lower organisms enable relatively quick
assessment of the functional conse-
quences of genetic variability at a partic-
ular locus. These data shed light on
underlying mechanism and guide the
astute clinical investigator in the early
uses of new genetic diagnostics. This
approach is particularly useful when it
would take much time (often years) to
collect the number of patients necessary
to rigorously address an important clin-
ical question. An example is the
scenario currently facing the bariatric
community. Multiple loci have been
convincingly associated with obesity.
The question posed is this: do variants
that predispose to obesity also result in
resistance to therapy? While not
necessarily important for most pharma-
ceuticals, which are safe and easily
reversible, this question is relevant in
particular for surgical interventions,
which carry a higher risk of morbidity
and mortality. Basic research can
provide novel biological insights
regarding both disease susceptibility
and therapeutic resistance and therefore
will greatly impact the practice of medi-
cine in the future, especially as the
library of susceptibility loci continues to
grow., March 16, 2012 ª2012 Elsevier Inc. 1077
Cancer Battle Plan
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To paraphrase a well-known Nobel
laureate, ‘‘There are a lot of people
studying cancer, but maybe we could
cure cancer if wewould just do it.’’ Factors
initiatinganddrivinghuman tumorsare infi-
nitely more complex than imagined when
the war on cancer was declared decades
ago. The naively brash enthusiasm for
a rapid conquest in the 1970s and 1980s
has been replaced by steady determina-
tion, strategic scientific advances, and
a growing number of victories that will
eventually win the war. The definition of
‘‘winning the war’’ has also evolved over
the years, from complete and permanent
cures for all cancer patients to re-estab-
lishing a durable symptom-free state of
equilibrium. In confronting the diversity
and mutability of human cancers, basic
scientists and translational oncologists
can perhaps have the greatest clinical
impact by discovering vital tumor-associ-
ated molecules or pathways for targeted
drug development and by defining
biomarkers predictive of clinical response.
These goals are often approached from
agenetic vantagepoint, andclinical results
such as those from targetingmutant BRAF
in melanoma or BCR/ABL in CML provide
strong proof of principle. However,
specific targets relevant to cancer immu-
nology, metabolism, and epigenetics are
equally as important although somewhat
more difficult to conceptualize and vali-
date. It is rapidly becoming appreciated
that rational synergistic combination ther-
apies supported by strong basic science,
rather thanmonotherapies, will be needed
to achieve our goals.1078 Cell 148, March 16, 2012 ª2012 ElsevieGWAS Follow Up for CVD
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Cardiovascular disease is the number one
killer worldwide. We have very few medi-
cations that have been proven to reduce
the risk of cardiovascular disease, in part
because the pathogenetic mechanisms
still remain to be fully determined. Epide-
miological work done half a century ago
led to recognition of the ‘‘traditional’’ risk
factors for disease—high cholesterol,
hypertension, diabetes, tobacco use,
etc. Preventive cardiology has largely
focused on managing these risk factors
with therapeutic lifestyle changes and,
when warranted, medications. But
despite our best efforts, millions of
patients still develop disease.
The Human Genome Project has led to
the development of powerful new genetic
techniques such as genome-wide associ-
ation mapping and whole-exome
sequencing. The application of these
unbiased techniques to patients with
cardiovascular disease is now illuminating
novel risk factors about which we had no
previous knowledge—themost prominent
examplebeingagenetic locusonchromo-
some 9p21, which remains a mystery.
Basic research is sorely needed to
undertake the difficult work of deter-
mining the molecular mechanisms that
underlie these novel risk factors. The
hope is that, as we gain a better under-
standing of these mechanisms, we will
be able to craft therapies that target the
novel risk factors and thereby comple-
ment existing medications, with the goal
of sharply reducing the number of people
suffering and dying from cardiovascular
disease.r Inc.A Cure for HIV
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Combination antiretroviral therapy (cART)
has transformed HIV/AIDS from an almost
invariably fatal disease to one that can be
successfully managed for decades.
However, it is extremely unlikely that we
will have the financial or operational
capacity to provide a lifetime of cART to
everyone who requires it, especially as
7,000 new infections occur daily. In addi-
tion, patients receiving long-term cART
can experience drug toxicities, drug resis-
tance, and even treatment failures. There-
fore, the imperative to develop a cure for
HIV looms large. In this case, cure is
defined as the lack of virus replication in
the absence of therapy. The basic
research with the greatest potential
impact involves finding innovative
approaches to eradicate or permanently
suppress the virus, thereby eliminating
the need for lifelong antiretroviral therapy.
The impact of a cure would be profound
for individuals and society. Patients would
be spared the cumulative effects of drug
toxicities; they would almost certainly
not transmit the virus to others; and the
considerable resources spent on cART
would be freed up for other services. In
this regard, an intensive basic research
effort is underway to delineate the precise
mechanisms whereby HIV persists
despite effective therapy. Such informa-
tion will be used to develop novel
interventions to eliminate or permanently
suppress the recalcitrant reservoirs of
HIV not eliminated with current
therapies. A cure for HIV would be truly
transformative.
